Cardinal Health 414 Company Profile

✉ Email this page to a colleague

CARDINAL HEALTH 414 has five approved drugs.

There are two US patents protecting CARDINAL HEALTH 414 drugs.

There are thirty patent family members on CARDINAL HEALTH 414 drugs in twelve countries and seventy-one supplementary protection certificates in nine countries.

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cardinal Health 414	TECHNETIUM TC 99M SESTAMIBI	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	078809-001	Apr 28, 2009	AP	RX	No	No		⤷ Subscribe				⤷ Subscribe
Cardinal Health 414	TECHNETIUM TC-99M MEDRONATE KIT	technetium tc-99m medronate kit	INJECTABLE;INJECTION	018107-001	Approved Prior to Jan 1, 1982	AP	RX	No	No		⤷ Subscribe				⤷ Subscribe
Cardinal Health 414	LYMPHOSEEK KIT	technetium tc-99m tilmanocept	INJECTABLE;INJECTION	202207-001	Mar 13, 2013		RX	Yes	Yes	6,409,990	⤷ Subscribe		Y		⤷ Subscribe
Cardinal Health 414	FLUDEOXYGLUCOSE F18	fludeoxyglucose f-18	INJECTABLE;INTRAVENOUS	203603-002	Sep 27, 2018	AP	RX	No	Yes		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
Australia	2010208624	⤷ Subscribe
European Patent Office	2392012	⤷ Subscribe
World Intellectual Property Organization (WIPO)	0069473	⤷ Subscribe
Japan	2015164933	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203431	CA 2015 00014	Denmark	⤷ Subscribe	PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
3347352	2290051-8	Sweden	⤷ Subscribe	PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REG. NO/DATE: EU/1/22/1671 20220819
2666774	CR 2020 00037	Denmark	⤷ Subscribe	PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
2465580	SPC/GB21/030	United Kingdom	⤷ Subscribe	PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.